孕19-23周母体心脏功能对子痫前期的预测价值
前瞻性观察研究纳入2853例妊娠,在19+1至23+3周记录8项母体心脏指标及MAP、UtA-PI、PlGF、sFlt-1,随访至分娩。76例(2.7%)发生子痫前期。校正母体特征和病史后,仅外周血管阻力受后续子痫前期显著影响;将其加入母体因素与生物标志物筛查未改善检出率。
要点
- 子痫前期孕妇在19-23周已出现心脏几何构型改变、心肌功能受损和外周血管阻力增高。
- 校正母体特征和病史后,仅外周血管阻力与后续子痫前期显著相关。
- 外周血管阻力未改善母体因素联合MAP、UtA-PI、PlGF、sFlt-1对子痫前期的筛查性能。
关键影像表现/征象
- 后续发生子痫前期的妊娠在19-23周已存在心脏几何构型改变、心肌功能受损和外周血管阻力增高的证据。
- 全部母体心血管指标均受与子痫前期风险增高相关的母体人口学特征和病史要素的显著影响。
- 校正母体人口学特征和病史后,唯一受后续子痫前期显著影响的心血管指标是外周血管阻力。
- 外周血管阻力中位数倍数(MoM)与MAP MoM相关,因血压参与两者估算。
- 多个心血管指标与MAP MoM弱相关,但均不与UtA-PI、PlGF或sFlt-1的MoM值相关。
诊断标准与关键数值
- 子痫前期定义为筛查后发生并至分娩,研究人群2853例中76例(2.7%)发生子痫前期。
- 筛查性能评估条件为10%假阳性率下,结局为<37周分娩的子痫前期或任何孕周分娩的子痫前期。
- 在母体人口学特征和病史筛查、或母体因素联合MAP、UtA-PI、PlGF和sFlt-1筛查基础上,加入外周血管阻力未改善对<37周分娩子痫前期或任何孕周分娩子痫前期的检出率。
临床应用与阅片要点
- 原文结论为母体心脏功能评估可提供子痫前期病理生理信息,但对子痫前期预测无用。
- 原文指出外周血管阻力MoM与MAP MoM相关,因血压参与两者的估算。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: First, to examine the factors from maternal characteristics and medical history that affect maternal cardiovascular indices, and, second, to examine the potential value of maternal cardiovascular indices at 19-23 weeks' gestation, on their own and in combination with maternal factors and the established biomarkers of pre-eclampsia (PE), including uterine artery pulsatility index (UtA-PI), mean arterial pressure (MAP), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1), in the prediction of subsequent development of PE.
METHODS: This was a prospective observational study in women attending for a routine hospital visit at 19 + 1 to 23 + 3 weeks' gestation. This visit included recording of maternal demographic characteristics and medical history, assessment of maternal E/A ratio, E/e' ratio, myocardial performance index, global longitudinal systolic strain, left ventricular ejection fraction, peripheral vascular resistance, left ventricular cardiac output and left ventricular mass indexed for body surface area, and measurement of MAP, UtA-PI, serum PlGF and serum sFlt-1. The measurements of the eight maternal cardiac indices were standardized to remove the effects of maternal characteristics and elements from the medical history. The competing-risks model was used to estimate the individual patient-specific risks of delivery with PE and determine the detection rate, at a 10% false-positive rate, in screening by a combination of maternal demographic characteristics and medical history with biomarkers.
RESULTS: The study population of 2853 pregnancies contained 76 (2.7%) that developed PE. In pregnancies that subsequently developed PE, there was evidence of altered cardiac geometry, impaired myocardial function and increased peripheral vascular resistance. All maternal cardiovascular indices were affected significantly by maternal demographic characteristics and elements of medical history known to be associated with an increased risk for subsequent development of PE. After adjustment for maternal demographic characteristics and medical history, the only cardiovascular index that was affected significantly by subsequent development of PE was peripheral vascular resistance. Peripheral vascular resistance multiples of the median (MoM) was correlated with MAP MoM, which is not surprising because blood pressure is involved in the estimation of both. There were weak correlations between several cardiovascular indices and MAP MoM, but none was correlated with MoM values of UtA-PI, PlGF or sFlt-1. The performance of screening for delivery with PE at < 37 weeks' gestation or delivery with PE at any gestational age in screening by maternal demographic characteristics and medical history or combinations of maternal factors with MAP, UtA-PI, PlGF and sFlt-1 was not improved by the addition of peripheral vascular resistance.
CONCLUSION: Assessment of maternal cardiovascular function provides information on the pathophysiology of PE but is not useful in the prediction of PE. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Gibbone E, Wright A, Vallenas Campos R, et al. Maternal cardiac function at 19-23 weeks' gestation in prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2021. PMID: 33294998. doi:10.1002/uog.23568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。